Linked Life Data

20017830

Source:http://linkedlifedata.com/resource/pubmed/id/20017830

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-12-18
pubmed:abstractText
The increasing number of patients requiring renal replacement therapy poses a challenge to maintain quality of care in the setting of limited resources. The commonly used modalities include hemodialysis and peritoneal dialysis, and using a "urea-centric" model to increase the clearance of small molecular weight uremic toxins beyond current guidelines does not appear to confer additional clinical benefits in terms of morbidity and mortality. Convective therapies including hemofiltration and hemodiafiltration, which also have higher middle molecule clearances, might offer significant benefits compared to diffusive therapy. We review the available evidence on convective therapies and their effects on middle molecular weight uremic toxins, particularly beta2 microglobulin because of its known associated morbidity. It is the authors' opinion that more emphasis should be placed on true uremic toxins such as beta2 microglobulin rather than surrogate uremic toxins like urea. Larger studies are also needed to study the merits of convective therapies, with a focus on cardiovascular morbidity and mortality.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1525-139X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
610-4
pubmed:meshHeading
pubmed:articleTitle
Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence.
pubmed:affiliation
Department of Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
pubmed:publicationType
Journal Article, Review